Additionally, the tumor microenvironment can impact EMT and therapeutic resistance, and the use of in vitro or xenograft models in immunodeficient mice may not accurately mimic the tumor microenvironment observed in patients who have developed acquired resistance to EGFR inhibitors. The gene discussed is EGFR; the disease is neoplasm.